Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
A study conducted using electronic health record data from a collective of U.S. health care systems found that most adults with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within one year. Discontinuation rates were significantly higher and reinitiation rates were significantly lower for patients without type 2 diabetes.
What are the side effects of GLP-1 medications? A researcher explains
GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings. However, over the past few years, these medications have become popular due to their weight loss and weight management benefits. Dr. Saundra Nguyen, assistant professor of internal medicine at Baylor College of Medicine, explains the side effects of GLP-1s.
Boosting protein BCL6 could help GLP-1 users retain muscle while losing fat
About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn’t discriminate between fat and muscle. Patients using GLP-1 drugs can experience rapid and substantial muscle loss, accounting for as much as 40% of their total weight loss. So how can we lose weight without also losing critical muscle?
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
Audience: Industry October 2, 2024 — The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022…